File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3109/10428190903406798
- Scopus: eid_2-s2.0-77249148314
- PMID: 19925050
- WOS: WOS:000274878800021
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells
Title | Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells |
---|---|
Authors | |
Keywords | Bone marrow Lymphoid leukemic cells Mesenchymal stromal cell Stromal suppression Vincristine |
Issue Date | 2010 |
Publisher | Informa Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal |
Citation | Leukemia And Lymphoma, 2010, v. 51 n. 3, p. 515-522 How to Cite? |
Abstract | Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from l-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ALL cells. As a consequence, they can help to re-establish the cytotoxic potential of l-asparaginase on ALL cells even under MSCs support. In our study, pre-treating human MSCs with VCR but not IM, markedly reduced the protective capacity of MSCs. Furthermore, differential rescue effects were observed during addition of exogenous l-asparagine to co-culture with or without VCR pre-treatment. This supported the postulation that VCR could suppress the protective effect of MSCs to ALL cells by suppressing l-asparagine secretion. Our results suggested that the combined VCR and l-asparaginase treatment in ALL were synergistic and VCR can serve as an effective agent in suppressing the leukemic marrow microenvironment. © 2010 Informa Healthcare USA, Inc. |
Persistent Identifier | http://hdl.handle.net/10722/163294 |
ISSN | 2023 Impact Factor: 2.2 2023 SCImago Journal Rankings: 0.790 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, KL | en_US |
dc.contributor.author | Liang, RHS | en_US |
dc.contributor.author | Chan, GCF | en_US |
dc.date.accessioned | 2012-09-05T05:29:45Z | - |
dc.date.available | 2012-09-05T05:29:45Z | - |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Leukemia And Lymphoma, 2010, v. 51 n. 3, p. 515-522 | en_US |
dc.identifier.issn | 1042-8194 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163294 | - |
dc.description.abstract | Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from l-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ALL cells. As a consequence, they can help to re-establish the cytotoxic potential of l-asparaginase on ALL cells even under MSCs support. In our study, pre-treating human MSCs with VCR but not IM, markedly reduced the protective capacity of MSCs. Furthermore, differential rescue effects were observed during addition of exogenous l-asparagine to co-culture with or without VCR pre-treatment. This supported the postulation that VCR could suppress the protective effect of MSCs to ALL cells by suppressing l-asparagine secretion. Our results suggested that the combined VCR and l-asparaginase treatment in ALL were synergistic and VCR can serve as an effective agent in suppressing the leukemic marrow microenvironment. © 2010 Informa Healthcare USA, Inc. | en_US |
dc.language | eng | en_US |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal | en_US |
dc.relation.ispartof | Leukemia and Lymphoma | en_US |
dc.rights | Leukemia and Lymphoma. Copyright © Informa Healthcare. | - |
dc.subject | Bone marrow | - |
dc.subject | Lymphoid leukemic cells | - |
dc.subject | Mesenchymal stromal cell | - |
dc.subject | Stromal suppression | - |
dc.subject | Vincristine | - |
dc.subject.mesh | Antineoplastic Agents - Pharmacology | en_US |
dc.subject.mesh | Asparaginase - Metabolism | en_US |
dc.subject.mesh | Bone Marrow Cells - Cytology | en_US |
dc.subject.mesh | Coculture Techniques | en_US |
dc.subject.mesh | Drug Screening Assays, Antitumor | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Inhibitory Concentration 50 | en_US |
dc.subject.mesh | Leukemia, Lymphoid - Drug Therapy - Pathology | en_US |
dc.subject.mesh | Mesenchymal Stem Cells - Cytology | en_US |
dc.subject.mesh | Mesoderm - Metabolism | en_US |
dc.subject.mesh | Models, Biological | en_US |
dc.subject.mesh | Piperazines - Pharmacology | en_US |
dc.subject.mesh | Pyrimidines - Pharmacology | en_US |
dc.subject.mesh | Stromal Cells - Metabolism | en_US |
dc.subject.mesh | Tetrazolium Salts - Pharmacology | en_US |
dc.subject.mesh | Vincristine - Pharmacology | en_US |
dc.title | Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells | en_US |
dc.type | Article | en_US |
dc.identifier.email | Liang, RHS:rliang@hku.hk | en_US |
dc.identifier.email | Chan, GCF:gcfchan@hkucc.hku.hk | en_US |
dc.identifier.authority | Liang, RHS=rp00345 | en_US |
dc.identifier.authority | Chan, GCF=rp00431 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.3109/10428190903406798 | en_US |
dc.identifier.pmid | 19925050 | - |
dc.identifier.scopus | eid_2-s2.0-77249148314 | en_US |
dc.identifier.hkuros | 179091 | - |
dc.identifier.hkuros | 163812 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77249148314&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 515 | en_US |
dc.identifier.epage | 522 | en_US |
dc.identifier.isi | WOS:000274878800021 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Fung, KL=36632178100 | en_US |
dc.identifier.scopusauthorid | Liang, RHS=26643224900 | en_US |
dc.identifier.scopusauthorid | Chan, GCF=16160154400 | en_US |
dc.identifier.issnl | 1026-8022 | - |